Pharmaceuticals

The Italian Trade Promotion Section in Tokyo coordinates the participation of 19 leading pharmaceutical companies at CPhI Japan 2025, reinforcing Italy’s role as a top supplier of active pharmaceutical ingredients and cutting-edge solutions.

New reports and webinars are provided as part of the Centre’s support for EU Business in Japan. This section provides valuable information for European Union companies seeking clear guidelines for trading, investing, or partnering with Japanese entities.

On 7-12 October, the EU-Japan Centre for Industrial Cooperation organised its annual business mission in the Life Sciences field. 10 SMEs from 7 EU countries participated in the 5-day mission.

MOIRe is an annual open innovation research program for drug discovery initiated by Mochida Pharmaceutical Co., Ltd, a large Japanese pharmaceutical company. Application form and more detailed information available online.

CCI Région Bourgogne Franche-Comté is organizing a B2B matching event within the frame of the scientific congress Innovative Therapies Days.

NEC strengthens its European life science activities where AI technology, biomedical science and ICT combine to develop advanced therapies for patients across the globe. Central and Northern Europe’s vivid entrepreneurial and scientific environment, and the European clinical network and regulatory infrastructure, help drive developments in immunotherapies.

The Trade Promotion Section of the Italian Embassy has organized a national pavilion at the 20th edition of CPHI JAPAN (19-21 April 2023) with 13 companies. The aim of the participation to the tradeshow was to promote the excellence of Made in Italy, to show the high level of development achieved by Italian production techniques, and to strengthen the presence of the Italian pharmaceutical industry in the Japanese market, increasing the business opportunities for the companies.

Asahi Kasei Pharma has announced the new application period for their annual “Open Innovation” solicitation of proposals for drug discovery research.